Life Sciences

  • July 21, 2026

    A&O Shearman Hires Davis Polk Restructuring Pro In NY

    Allen Overy Shearman Sterling has hired a former Davis Polk & Wardwell LLP counsel as a restructuring partner in New York.

  • July 20, 2026

    Moderna Hits CureVac With Countersuit In COVID Vax Fight

    Moderna has filed a countersuit in Delaware federal court against a BioNTech subsidiary's claims that Moderna's COVID-19 vaccine infringed several patents, saying the rival biotech company was trying to "take credit" for Moderna's own innovations in mRNA vaccines.

  • July 20, 2026

    Albertsons Data Suggests Opioids Were Diverted, Expert Says

    Albertsons pharmacies in Washington state received considerably more opioid medications from distributors between 2009 and 2015 than the company reported dispensing — a sign of potential diversion, according to an expert witness who testified Monday at a bench trial in Washington's lawsuit accusing the chain of exacerbating the state's opioid crisis.

  • July 20, 2026

    Apple Can't Get Judge To Toss Masimo's $634M Patent Verdict

    Apple has lost its bid to dodge a jury's finding that it owes $634 million for infringing a Masimo Corp. patent after a California federal judge rejected the tech giant's challenge to how the court construed a key term and its bid for a new trial.

  • July 20, 2026

    SD Judge Blocks Abortion Ad Ban Against Atty, Nonprofit

    A South Dakota federal judge barred the state from enforcing an abortion advertising ban against a reproductive health education nonprofit and an attorney, ruling that doing so would likely violate the First Amendment.

  • July 20, 2026

    Latham, Cooley Steer $1.5B Tempus Cancer Testing Deal

    Chicago-based Tempus AI said Monday it has agreed to acquire cancer diagnostics company Personalis in a deal with an enterprise value of about $1.5 billion, with Latham & Watkins LLP and Cooley LLP advising, respectively.

  • July 20, 2026

    Vanda's NDA Rejection Challenge Can't Be Heard At DC Court

    A D.C. federal judge has said he no longer has jurisdiction to hear Vanda Pharmaceuticals Inc.'s challenge alleging the FDA violated the Appointments Clause by allowing a non-officer to exercise "signatory authority" and reject its new drug application for tradipitant, since Vanda went to the D.C. Circuit raising the same argument already.

  • July 20, 2026

    Trump Demands Review Of Judges' Science Manual

    President Donald Trump has escalated a recent controversy over a scientific manual for federal judges that has been around for over three decades. 

  • July 20, 2026

    4 Patent Cases To Watch In The Second Half Of 2026

    New limits on the ability to challenge patents tied to when they were issued, the invalidity standards for antibody patents and the test for design patent infringement are all at issue in cases patent attorneys will be monitoring for the rest of the year.

  • July 20, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week tackled disputes involving intellectual property, corporate control, fiduciary duties, artificial intelligence, trust administration and cryptocurrency litigation.

  • July 17, 2026

    Taylor Farms, Taco Bell Sued Over Cyclospora Outbreak

    Taylor Farms and Taco Bell are facing proposed class litigation in California, Michigan and Ohio federal courts after public health officials linked contaminated lettuce that was supplied to Taco Bell to a parasitic outbreak that's sickened more than 1,600 people in several states.

  • July 17, 2026

    US Seeks Toss Of Arbutus Patent Suit Over Moderna Vaccine

    The federal government asked the U.S. Court of Federal Claims on Friday to dismiss much of a patent suit against it by Arbutus Biopharma tied to Moderna's COVID-19 vaccine, saying the court couldn't hear the bulk of the case because Arbutus and Moderna reached a multibillion-dollar consent judgment that is subject to appeal.

  • July 17, 2026

    Ex-Hospital Exec Can't Cite Tainted Jury To Ditch Fraud Case

    A former Chicago hospital executive who is fighting extradition to face federal prosecutors' $239 million COVID-19 testing fraud charges cannot seek the same grand jury misconduct-based dismissal his former co-defendants received until he submits himself to the Northern District of Illinois' jurisdiction, a federal judge has ruled.

  • July 17, 2026

    Fed. Circ. Won't Review Reversal In $18M Penile Implant Case

    The full Federal Circuit said Friday that it won't review a panel decision that mostly undid a California federal jury verdict that awarded $18.3 million to International Medical Devices Inc. in a trade secret case about penile implants.

  • July 17, 2026

    Md. Judge Stays Reforms Set To Shrink ACA Coverage Pool

    A Maryland federal judge stayed a set of Affordable Care Act marketplace reforms that were set to take effect Monday, finding several cities and groups representing doctors and small businesses were likely to succeed in their Administrative Procedure Act challenge against them.

  • July 17, 2026

    Drug Buyers' $62M Generic-Pricing Deal Gets Final OK

    A federal judge granted final approval to wholesalers on settlements worth a total of at least $62 million with Glenmark Pharmaceutical Inc., Pfizer Inc. and Pfizer subsidiary Greenstone LLC over claims the companies colluded with others to keep generic drug prices high, according to court orders.

  • July 17, 2026

    Mass. Drug Co. To Pay $4.7M To Resolve Kickback Claims

    A Massachusetts-based pharmaceutical company has agreed to pay $4.7 million to settle allegations that it paid illegal kickbacks to physicians to induce them to buy a drug that treats eye inflammation, the U.S. Department of Justice said Friday.

  • July 17, 2026

    Medical Groups Urge 1st Circ. To Back Vaccine Panel Freeze

    The American Academy of Pediatrics and other public health organizations on Friday defended before the First Circuit a Massachusetts judge's decision to block Health Secretary Robert F. Kennedy Jr.'s vaccine policy committee appointments, countering claims that the judge overreached.

  • July 17, 2026

    DaVita Wins Bid To Decertify 1,300-Member Collective

    A Colorado federal judge dismantled a collective action brought by DaVita nurses and technicians alleging the kidney care giant forced them to work through unpaid meal breaks, finding Friday that the roughly 1,300 workers' vastly different experiences made collective treatment impossible.

  • July 17, 2026

    Taxation With Representation: Freshfields, Slaughter And May

    In this week's Taxation With Representation, Uber Technologies Inc. buys food delivery company Delivery Hero SE, engineering group ABB Ltd. acquires flow technology company Rotork PLC, and Eli Lilly and Co. buys drug developer AtaiBeckley Inc.

  • July 17, 2026

    The Biggest Trade Secret Rulings Of 2026: A Midyear Report

    The Federal Circuit issued two of the year's most consequential trade secret rulings within days of each other, wiping out Insulet's victory in a wearable insulin patch pump case while reopening a software company's path to potentially larger damages in a dispute with Ford Motor Co. Here, Law360 highlights the biggest trade secret decisions so far this year.

  • July 17, 2026

    UK Litigation Roundup: Here's What You Missed In London

    The past week in London has seen Snapchat and Dolby press on with a fresh infringement claim in their ongoing patent battle, The Telegraph face an intellectual property claim by a photo archive, a group of international human rights barristers and chambers sued, and oil business Equinor embroiled in a contract dispute with BP after recently acquiring full ownership in their offshore project. Here, Law360 looks at these and other new claims in the U.K.

  • July 17, 2026

    Commerce Opens Duty Probes Into Chinese Supplements

    The U.S. Department of Commerce is investigating whether certain dietary supplements imported from China are being sold at unfair prices and should be subject to antidumping and countervailing duties, it said Friday.

  • July 16, 2026

    FDA, Drugmakers Urge 5th Circ. To Allow Abortion Pill By Mail

    The U.S. Food and Drug Administration and the makers of the abortion medication mifepristone have urged the Fifth Circuit not to reinstate an in-person dispensing requirement, arguing that doing so would disrupt the government's ongoing review of the drug, "threaten chaos" and defy the U.S. Supreme Court.

  • July 16, 2026

    Pharma Co. Beats Investor Suit Over Prostate Drug Trial

    A Wisconsin federal judge ruled Wednesday that investors of prostate cancer treatment developer Essa Pharma Inc. have not shown they were misled by the company on the efficacy of its lead drug candidate, which was not as effective as an existing treatment for certain cancer patients in a terminated clinical trial.

Expert Analysis

  • Why Biotech Cos. Need Litigation Plans Before Bad News

    Author Photo

    Biotech companies should take proactive steps to respond to the growing trend of securities litigation filed against them, due to the inherently uncertain nature of their business models and heightened scrutiny of clinical trial disclosures, regulatory communications and investor-facing statements, says Wesley Horton at FBFK.

  • 10 Years, 150 Cases: The Rise And Fall Of Post-Halo Damages

    Author Photo

    When the U.S. Supreme Court decided Halo v. Pulse in 2016, patent practitioners predicted that enhanced damages would become easier to win, but analysis of every contested district court ruling on a motion for enhanced damages in the last 10 years shows that courts have shown increasing restraint, say attorneys at Reichman Jorgensen.

  • Legal Risks Of Using AI To Screen Psychedelic Trial Patients

    Author Photo

    Though using artificial intelligence to preemptively identify drug trial participants likely to experience placebo effects could produce clearer research results, sponsors will need to be ready for the new legal questions these methods raise about informed consent, accountability for algorithmically derived criteria, and potential bias in data training sets, says Kimberly Chew at Husch Blackwell.

  • After Durnell, Connecting Science And Causation Will Be Key

    Author Photo

    The U.S. Supreme Court's June 25 decision in Monsanto v. Durnell narrowed label-based failure-to-warn claims — meaning that going forward, viable theories will depend even more on whether experts can reliably connect scientific evidence to the causal proposition the law requires, says Alex Smolak at Weill Cornell Medicine-Qatar.

  • Series

    Choral Singing Makes Me A Better Lawyer

    Author Photo

    Singing in the New York City Bar Chorus — a hobby partly inspired by the late U.S. District Judge Richard Owen, who infused my clerkship year with opera music — has improved my legal career by refining my abilities to listen, exude confidence and develop emotional intelligence, says Bonnie Baker at Friedman Kaplan.

  • Attorney Mental Health Is An Ethical Obligation In The AI Era

    Author Photo

    As attorneys cope with the increasing unpredictability that artificial intelligence and constant policy changes have created, particularly in practice areas where they carry the emotional weight of clients’ most consequential life events, otherwise soft discussions about self-care are a matter of professional competence, says attorney Jack Jrada.

  • The Case For Using Final-Offer Damages Forms In IP Suits

    Author Photo

    Recent Federal Circuit decisions, such as Ollnova v. Ecobee, that scrutinize verdict forms in patent infringement disputes potentially render the final-offer damages selection procedure more attractive, though it should not be seen as a replacement for patent damages doctrine, says Brandon Theiss at Addy Hart.

  • Key Tips For Patenting Antibody-Drug Conjugate Inventions

    Author Photo

    Recent decisions highlight the significant challenges that can arise when patenting antibody-drug conjugates, which require strategic considerations for satisfying heightened written description and enablement requirements, says Xiaoban Xin at FisherBroyles.

  • $885M IBS Drug Verdict Tests Pay-For-Delay Limits

    Author Photo

    The outcome in the Amitiza Antitrust Litigation is significant because it is the first jury trial win for private antitrust plaintiffs in a suit challenging a patent settlement reverse payment since the U.S. Supreme Court adopted the rule-of-reason legal framework in 2013, offering a blueprint for pay-for-delay claims, say attorneys at Katten.

  • Series

    Power To The Paralegals: Burnout As A Structural Problem

    Author Photo

    Law firm leadership can best retain their paralegals not by encouraging self-care, but by seeking top-down structural solutions for the quiet proliferation of responsibilities and the vicarious exposure to client trauma that particularly drive burnout in this vital role, says Erika Sneeringer at Brockstedt Mandalas.

  • Class Actions At The Circuit Courts: June Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses five recent rulings from cases involving allegations of internet data misuse, consumer fraud claims, immigration, insurance and First Amendment violation claims.

  • Takeaways From 1st Del. Ruling Applying Moelis Amendments

    Author Photo

    Delaware corporations should carefully review contractual arrangements and governance documents following the Court of Chancery's recent enforcement of a non-Delaware forum selection clause in a CEO's employment agreement under 2024 amendments to the state's General Corporation Law, say attorneys at Morgan Lewis.

  • Ill. Law Firm MSO Bill Clashes With Court Power, Ethics Rules

    Author Photo

    An Illinois bill prohibiting law firms from certain business arrangements with management service organizations, sent to the governor for signature last week, encroaches upon the courts' constitutional powers and goes beyond the Illinois Rules of Professional Conduct in regulating investment in law-related services, says Matthew O’Hara at Smith Gambrell.

  • The Future Of WDTX Patent Litigation After Judge Albright

    Author Photo

    With U.S. District Judge Christopher Wolfe set to take over much of Judge Alan Albright's patent infringement docket in the Western District of Texas later this year, attorneys should prepare for potential differences in Judge Wolfe's approach to the court's high volume of patent litigation, say attorneys at Sidley Austin.

  • Opinion

    State Courts Must Be Gatekeepers Of Expert Testimony

    Author Photo

    Based on my experience in the state judiciary, emulating federal courts' role as gatekeepers of expert witness testimony would help state court judges maintain the appearance of impartiality and assist juries, thus enhancing the overall confidence people have in their justice system, says Lorie Gildea at Greenberg Traurig.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.